Cancer prevalence increases with aging. Prevalent or incident neurocognitive disorders are frequent in geriatric oncology. Cognitive decline associated with cancer increases the risk of under or over-cancer treatment and makes therapeutic decisions complex. In this context, we present tools to optimize cognitive impairment screening, identification of underlying mechanisms and specific treatments. Geriatric specialists intervention can help global care, social services utilization and patient's orientation when ambulatory cares become difficult.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bulcan.2018.04.006 | DOI Listing |
BMC Oral Health
January 2025
Department of Operative Dentistry, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand.
Background: This in vitro study evaluated the efficacy of professional and home-use fluoride regimens for protecting irradiated enamel, undergoing pH cycling resembling xerostomia.
Methods: Sixty human premolar teeth were irradiated with a total dose of 70 Gy and subsequently sectioned into 3 × 3 cm enamel slabs. These slabs were randomly distributed into five groups (n = 12 per group): professional-use groups received fluoride varnish either weekly (FV1) or biweekly (FV2); home-use groups applied 5000 ppm (FT5) or 1450 ppm (FT) fluoride toothpaste; and a control group (control) received no treatment.
Clin Colorectal Cancer
December 2024
Austin Hospital, Heidelberg, Victoria, Australia.
Background: Panitumumab (pan) plus chemotherapy is a preferred first-line therapy for unresectable RAS and BRAF wild type metastatic colorectal cancer (mCRC). Older patients may not be suitable for combination regimens. We investigated 2 lower intensity pan-containing regimens.
View Article and Find Full Text PDFAJNR Am J Neuroradiol
January 2025
Department of Neurosurgery and Neurooncology (M.M., A.B., T.M., D.K., D.N.), First Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic.
Background And Purpose: Diffuse gliomas, a heterogeneous group of primary brain tumors, have traditionally been stratified by histology, but recent insights into their molecular features, especially the mutation status, have fundamentally changed their classification and prognosis. Current diagnostic methods, still predominantly relying on invasive biopsy, necessitate the exploration of noninvasive imaging alternatives for glioma characterization.
Materials And Methods: In this prospective study, we investigated the utility of the spherical mean technique (SMT) in predicting the status and histologic grade of adult-type diffuse gliomas.
Ther Adv Med Oncol
January 2025
Department of Oncology, Zhuzhou Second Hospital, Zhuzhou, Hunan 412000, China.
Background: Both the antibody-drug conjugate (ADC) enfortumab vedotin (EV) and programmed death-1 inhibitor pembrolizumab have been shown to provide survival benefits in patients previously treated with locally advanced or metastatic urothelial carcinoma (la/mUC). Cost-effectiveness is necessary to consider whether the increased efficacy of the two therapies will lead to higher prices for first-line treatment of previously untreated la/mUC.
Objectives: To guide the choice of EV plus pembrolizumab or chemotherapy for patients with previously untreated la/mUC.
Anaesthesia
January 2025
Anaesthetic Department, Royal Surrey Hospital Foundation Trust, Guildford, UK.
Introduction: Peri-operative medicine is becoming increasingly relevant in the context of managing frail patients with cancer. This paper outlines how demographic shifts in populations are affecting cancer incidence and frailty rates, the relevance this holds to the management of cancer care, and the outcome measures that should be used to gauge best clinical practice to ensure patient-centred care.
Methods: A targeted literature review was conducted using the search terms 'surgical oncology', 'outcomes', 'frailty', 'quality of life' and 'end of life' from 10 to 17 June 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!